Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital. Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association. As a senior investigator of the TIMI Study Group, he has been principal investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18 and PROVE IT, and the IMPROVE IT trial. Dr. Cannon now serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.

Dr. Michael Blazing graduated from UCSF medical school after receiving a BS in Biochemistry from UC Davis. He went on to do medical residency there. He came to Duke in 1991 where he fulfilled his Cardiology fellowship and stayed on as faculty. He has remained at Duke since 1991. His career began in a basic science laboratory where he was supported by an AHA grant. He moved to clinical research with the DCRI in 1998 and was one of the national Primary Investigators for the A to Z study. He moved from that study to be one of the national Primary Investigators of the IMPROVE-IT study. His clinical research interests lie in prevention. His clinical specialties are prevention and management of heart failure and difficult to control angina. He is board certified in both Cardiology and Advanced Heart Failure. He served as director of Cardiac Inpatient Services for 10 years and 2012 move to be director of Cardiovascular Outpatient Services at Duke.

Dr. Giugliano is an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital and Assistant Professor in Medicine at Harvard Medical School. He graduated Summa Cum Laude and Phi Beta Kappa majoring in Mathematics at Dartmouth College in 1985, and received his medical degree at Harvard Medical School in 1989. Dr. Giugliano completed his internship, residency, and chief residency in Los Angeles at Cedars-Sinai Medical Center, from 1989-93, then returned to Boston as a cardiology fellow at the Massachusetts General Hospital (1993-6). In 1996, Dr. Giugliano joined the Brigham and Women’s Hospital as a Research Fellow in Medicine working with the Thrombolysis in Myocardial Infarction (TIMI) Study Group under the direction of Eugene Braunwald, and completed a Masters of Science in epidemiology at the Harvard School of Public Health. In 1997, he joined the faculty in the Cardiovascular Division of the Brigham and Women’s Hospital. Research interests: novel antithrombotic and fibrinolytic agents, lipid-lowering therapies, assessment of outcomes in patients with ACS. He has authored >100 articles, >25 editorials/book chapters, and given hundreds of lectures nationally and internationally. Dr. Giugliano is the principal TIMI investigator for the EARLY ACS trial, and co-investigator and member of the Operations Committee for the IMPROVE-IT and for the ENGAGE-AF TIMI 48 Trials. Dr. Giugliano was the principal investigator at BWH of 4 additional trials, and has served on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. He is an active participant in the clinical activities in the Cardiovascular Division attending in the Cardiac Intensive Care Unit, telemetry unit, and consult services, and seeing patients in a busy outpatient practice. Dr. Giugliano lives in Westwood, MA with his wife and four children. Other interests: music, baseball, hockey, running, mathematics, gardening.

Harald Darius is Professor and Director of the Department of Cardiology, Vascular Medicine, Nephrology and Conservative Intensive Care Medicine at the Vivantes Neukoelln Medical Center in Berlin, Germany. Professor Darius’ research and publications focus on coronary heart disease, peripheral artery disease, and the assessment of cardiovascular risk. His main field of scientific expertise is the antithrombotic therapy during coronary interventions, the acute coronary syndrome or atrial fibrillation. He is member of numerous scientific societies including the German Cardiac Society,the German Society of Internal Medicine, the German and the International Society for Thrombosis and Haemostasis. He served as chairman of the Association of Leading Cardiological Hospital Physicians and acts as member on several scientific committees e.g. the Press Committee of the European Society of Cardiology. He was named fellow of the European Society, the American College of Cardiology and the American Heart Association. In addition to numerous book chapters and review articles, Professor Darius has published more than 100 scientific articles in peer reviewed journals and has been invited to speak as a keynote lecturer by numerous national and international scientific societies. Besides his activities in experimental research in the field of platelet-vessel wall interactions, thrombosis and vascular gene therapy, he has participated in numerous multicenter trials as a local principal investigator or national lead investigator in the areas of acute coronary syndrome, chronic stable angina, heart failure, and pulmonary hypertension. Professor Darius was born and raised in Cologne and trained Clinical Pharmacology, Internal Medicine, Cardiology and Intensive Care Medicine in Cologne, Philadelphia and Mainz.

Professor Basil S. Lewis is Director of the Cardiovascular Clinical Research Institute at the Lady Davis Carmel Medical Center in Haifa, Israel, and a Professor of Medicine at the Ruth and Bruce Rappaport School of Medicine of the Technion. Professor Lewis is a graduate of the University of the Witwatersrand in Johannesburg, South Africa (MB, BCh; D Med Sci) and undertook postgraduate training in Los Angeles, California. He was a tenured Professor of Medicine at UCLA. He is a Fellow of the Royal College of Physicians of London, the American College of Cardiology, the American Heart Association and the European Society of Cardiology. Professor Lewis is Chairman-Elect of the ESC Working Group for Cardiovascular Pharmacotherapy. He is a Past-President of the Israel Heart Society and Past-Governor of the ACC chapter in Israel. Professor Lewis has edited/co-edited nine books and is an author/co-author of more than 430 professional publications. He is an Associate Editor of the European Heart Journal: Cardiovascular Pharmacotherapy and also of Cardiology, serves on the editorial board of the Journal of the American College of Cardiology, Coronary Artery Disease, Heart Failure Reviews and is a regular reviewer for a number of other leading journals.

Wouter Jukema, MD, PhD, FESC, FACC, is professor of cardiology and chairman of “Leiden Vascular Medicine” at Leiden University Medical Center (LUMC) in the Netherlands. Furthermore he is co-chairman of the Dutch Atherosclerosis Society as well as past “established clinical investigator” of the Netherlands Heart Foundation”. His research focusses on the field of athero-thrombosis and includes atherosclerosis research as well as interventional cardiology (vascular biology, lipid modification, diabetes, anti-thrombotics/anti-platelets and genetics research) in humans as well as in transgenic animals. He has a large number of peer reviewed publications (with many in top journals like New England Journal of Medicine, Lancet, Nature Genetics, Nature Reviews, Jama, Circulation, JACC and EHJ) Prof. Jukema is principal investigator in several large athero-thrombosis studies, a member of various national and international athero-thrombosis boards and holder of multiple major (inter) national, a.o. European Union, grants.

Clinical cardiologist and clinical trials researcher with interest in prevention and treatment of cardiovascular disease. Leader in acute coronary syndromes, clinical trials and clinical event adjudication.